Scale Is a Test, Not a Triumph

by James ColeScience and Modalities Editor, HMND

The cleanest read on cell and gene therapy this week is that scale is getting decided in the least glamorous places, where a batch turns into a release decision, a transfer turns into a handoff, and a promising platform meets the stubborn fact that manufacturing still has to prove itself under pressure. Bristol Myers Squibb ending its Cellares partnership after the automation platform failed to meet commercial CAR T requirements says more about the field than a hundred celebratory slides ever could.

AAV sits in the same uncomfortable light. Potency still behaves like a moving target, and every time the field talks about standardization, the argument eventually runs into assay design, reference materials, and the ugly truth that a gene therapy can look elegant in discovery and still wobble when release testing has to speak for the product. The science is real. The measurement burden is real too.

Where the chain snaps

The FDA’s recent push toward flexibility for CGT manufacturing is an admission that the old regulatory frame was built for a different species of medicine. That flexibility can help, but only if teams can defend what they know with an evidence chain that holds together from process development to commercial supply, including prior knowledge, comparability, and phase appropriate release criteria.

This is where the software layer stops being background noise. If your batch record lives in one system, your potency trend in another, your comparability package in a PDF graveyard, and your transfer history in email, then every handoff becomes a new opportunity for doubt. Scale fails in those seams. The lab can make product, but the data system has to make the product legible across sites, assays, and regulators.

The part nobody puts on a slide

Picture a release team on a Thursday night, waiting on one assay result that may or may not be interpretable after a method change. The vector titer passed. The potency result did not align cleanly with the historical set. Now someone has to decide whether the deviation is biology, instrumentation, operator drift, or a platform assumption that was never stress tested hard enough.

That is the actual battlefield for cell and gene therapy. Regulatory flexibility helps only when the manufacturing execution system, quality data model, and interoperability between QC instruments and review workflows can preserve batch reality without laundering it into a prettier story. A digital twin sounds clever until the real batch arrives with a mixed history, a modified assay, and a question from QA that the model was never trained to answer.

The field keeps wanting a victory lap for the modality. The evidence says something harsher and more useful. Scale belongs to the teams that can carry science through release testing, comparability, and platform operations without losing the chain of truth on the way.

If that handoff problem is sitting in your program, hello@example.com is where the conversation starts.